Example: Heart Attack

Clinical Trials Sponsored by Corcept Therapeutics

Total 51 results

NCT04795479

Recruiting

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Conditions: Healthy
NCT04672512

Recruiting

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Conditions: Healthy
NCT04672499

Completed

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Conditions: Healthy
NCT04524403

Recruiting

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Conditions: Antipsychotic-induced Weight Gain (AIWG)
NCT04373265

Recruiting

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Conditions: Adrenocortical Carcinoma
NCT04329949

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
NCT04308590

Recruiting

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Conditions: Hypercortisolism
NCT04249323

Completed

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Conditions: Healthy Adults
NCT03878264

Completed

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Conditions: Healthy
NCT03877952

Completed

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Conditions: Healthy
NCT03877562

Completed

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Conditions: Antipsychotic-induced Weight Gain
NCT03823703

Recruiting

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Conditions: Nonalcoholic Steatohepatitis (NASH)
NCT03818256

Recruiting

This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Conditions: Antipsychotic-induced Weight Gain (AIWG)
NCT03776812

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT03697109

Recruiting

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Conditions: Cushing Syndrome
NCT03604198

Enrolling by invitation

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Conditions: Cushing Syndrome
NCT03540836

Completed

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Conditions: Healthy
NCT03512548

Completed

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Conditions: Healthy
NCT03508635

Completed

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Conditions: Healthy
NCT03457597

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Conditions: Healthy
NCT03442621

Completed

Relacorilant Food Effect Study in Healthy Subjects

Conditions: Healthy; Food-drug Interaction
NCT03437941

Recruiting

Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Conditions: Metastatic Castration-Resistant Prostate Cancer
NCT03379363

Terminated

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

Conditions: Hypercortisolism; Cushing Syndrome
NCT03335956

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Conditions: Healthy
NCT03315338

Completed

First-in-human Study in Healthy Subjects

Conditions: Healthy